{"id":"paliperdidone-er","safety":{"commonSideEffects":[{"rate":"10-20","effect":"Akathisia"},{"rate":"10-15","effect":"Extrapyramidal symptoms"},{"rate":"5-10","effect":"Weight gain"},{"rate":null,"effect":"Prolactin elevation"},{"rate":"10-15","effect":"Somnolence"},{"rate":"5-10","effect":"Headache"},{"rate":"5-10","effect":"Tachycardia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Paliperidone is the active metabolite of risperidone and works by antagonizing dopamine D2 receptors in mesolimbic and mesocortical pathways, which reduces positive symptoms of psychosis, while also blocking serotonin 5-HT2A receptors, which may enhance antipsychotic efficacy and reduce extrapyramidal side effects. The extended-release formulation provides sustained drug delivery over 24 hours, improving medication adherence and symptom control.","oneSentence":"Paliperidone ER is an atypical antipsychotic that blocks dopamine D2 and serotonin 5-HT2A receptors in the brain to reduce psychotic symptoms.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:59:35.922Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Schizophrenia"},{"name":"Schizoaffective disorder"},{"name":"Bipolar I disorder (acute and maintenance treatment)"}]},"trialDetails":[{"nctId":"NCT01592201","phase":"PHASE4","title":"A Comparative Study of Patient Satisfaction Between Continued Administration of Previous Antipsychotics Versus Switched Administration to Paliperidone ER in Non-satisfied Patients With Previous Antipsychotic Drug","status":"TERMINATED","sponsor":"Janssen Korea, Ltd., Korea","startDate":"2012-07","conditions":"Schizophrenia","enrollment":13}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":132262,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Paliperdidone ER","genericName":"Paliperdidone ER","companyName":"Janssen Korea, Ltd., Korea","companyId":"janssen-korea-ltd-korea","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Paliperidone ER is a small molecule antipsychotic medication used to treat schizophrenia. It is administered in an extended-release form.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}